3 terminated, 3 withdrawn, 2 completed, 1 recruiting. 7 Phase 1, 3 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 2, Terminated 2, Withdrawn 2, Recruiting 1 |
| Phase 2 | 3 | Recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 3 | 2 | Terminated 1, Withdrawn 1 |
Follow vocimagene amiretrorepvec: new trials by email Literature Review of vocimagene amiretrorepvec trials Research Report on vocimagene amiretrorepvec
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma DB107-RRV, DB107-FC, Radiation Therapy (RT) - High Grade Glioma, MGMT-Unmethylated Glioblastoma | Phase 1 / Phase 2 | Recruiting | University of California, San Francisco | 70 | 2025-01-08 | 2026-03-11 |
| Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma Extended Release Flucytosine, NovoTTF-100A Device, Quality-of-Life Assessment - Anaplastic Astrocytoma, Glioblastoma | Phase 2 / Phase 3 | Withdrawn | NRG Oncology | 2020-01-31 | 2026-05-07 | |
| A Study of Toca 511 & Toca FC in Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer (Toca 8) Toca 511, Toca FC (extended-release formulation of flucytosine) - Bladder Cancer | Phase 1 | Withdrawn | Tocagen Inc. | 2019-12-01 | 2020-03-30 | |
| A Study of the Safety of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Newly Diagnosed High Grade Glioma Receiving Standard of Care Toca 511, Toca FC - Newly Diagnosed High Grade Glioma (HGG) | Phase 1 | Withdrawn | Tocagen Inc. | 2017-01-01 | 2020-03-30 | |
| A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6) Toca 511, Toca FC - Colorectal Cancer, Triple Negative Breast Cancer | Phase 1 | Terminated | Tocagen Inc. | 21 | 2016-07-01 | 2020-02-07 |
| The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma Toca 511, Toca FC, Lomustine - Glioblastoma Multiforme, Anaplastic Astrocytoma | Phase 2 / Phase 3 | Terminated | Tocagen Inc. | 403 | 2015-11-30 | 2020-02-07 |
| Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor Toca 511, Toca FC - Glioblastoma Multiforme, Anaplastic Astrocytoma | Phase 1 | Completed | Tocagen Inc. | 17 | 2014-02-01 | 2018-05-21 |
| Study of a Retroviral Replicating Vector Combined With a Prodrug to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor Toca 511 vector, Toca FC - Glioblastoma Multiforme, Anaplastic Astrocytoma | Phase 1 | Completed | Tocagen Inc. | 58 | 2012-02-01 | 2018-05-21 |
| A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511 Toca 511 vector, Toca FC • Flucytosine • 5-FC • 5-Fluorocytosine - Glioblastoma Multiforme, Astrocytoma | Phase 1 | Terminated | Tocagen Inc. | 65 | 2011-02-01 | 2020-03-30 |
Astrocytoma (6) · Glioblastoma (6) · Glioma (4) · Oligodendroglioma (4) · Brain Neoplasms (3) · Urinary Bladder Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Head and Neck Neoplasms (1) · Lymphoma (1) · Melanoma (1) · Non-Muscle Invasive Bladder Neoplasms (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1) · Recurrence (1)
Tocagen Inc. (7) · NRG Oncology (1) · University of California, San Francisco (1)
United States (6) · Canada (1) · Israel (1) · South Korea (1)
Asha Das, MD (3) · Jaime R Merchan, MD (1) · Manmeet S Ahluwalia (1) · Michael Vogelbaum, MD, PhD, NS (1) · Nicholas Butowski, MD (1) · Noriyuki Kasahara, MD, PhD (1) · Steven Kalkanis, MD (1) · Timothy Cloughesy, MD (1) · Timothy Cloughesy, MD, NO (1)
PMID 27252174, PMID 29322091, PMID 29735994, PMID 29762717, PMID 33119048
U10CA180868 (1)